prikaz prve stranice dokumenta No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study
  Download
PDF 1.13 MB
Scientific paper - Original scientific paper
No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study
Heliyon, 10 (2024), 12; e32827. https://doi.org/10.1016/j.heliyon.2024.e32827
Krečak, Ivan; Bačić, Josipa Antonija; Šimunić, Nevena; Bušac, Vesna; Pivac, Ljerka; Čubrić, Eva; Skelin, Marko; Lucijanić, Marko

Cite this document

Krečak, I., Bačić, J. A., Šimunić, N., Bušac, V., Pivac, Lj., Čubrić, E. ... Lucijanić, M. (2024). No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study. Heliyon, 10. (12). doi: 10.1016/j.heliyon.2024.e32827

Krečak, Ivan, et al. "No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study." Heliyon, vol. 10, no. 12, 2024. https://doi.org/10.1016/j.heliyon.2024.e32827

Krečak, Ivan, Josipa Antonija Bačić, Nevena Šimunić, Vesna Bušac, Ljerka Pivac, Eva Čubrić, Marko Skelin and Marko Lucijanić. "No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study." Heliyon 10, no. 12 (2024). https://doi.org/10.1016/j.heliyon.2024.e32827

Krečak, I., et al. (2024) 'No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study', Heliyon, 10(12). doi: 10.1016/j.heliyon.2024.e32827

Krečak I, Bačić JA, Šimunić N, Bušac V, Pivac Lj, Čubrić E, and sur.. No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study. Heliyon [Internet]. 2024 June 11 [cited 2024 November 11];10(12). doi: 10.1016/j.heliyon.2024.e32827

I. Krečak, et al., "No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study", Heliyon, vol. 10, no. 12, June 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:314923. [Accessed: 11 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study
AuthorIvan Krečak
AuthorJosipa Antonija Bačić
AuthorNevena Šimunić
AuthorVesna Bušac
AuthorLjerka Pivac
AuthorEva Čubrić
AuthorMarko Skelin
AuthorMarko Lucijanić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Abstract (english)
The presence of steatotic liver disease (SLD) is associated with an increased cardiovascular risk in the general population. Chronic myeloproliferative neoplasms (MPNs), essential thrombocythemia (ET) and polycythemia vera (PV), are characterized by clonal myeloproliferation, chronic inflammatory state, and increased cardiovascular morbidity and mortality. The aim of this single-center study was to analyze clinical associations and the potential prognostic impact of SLD in ET and PV patients. We retrospectively included 108 patients (64 ET and 44 PV); median age was 70.5 years (range 21–92), 68 (63 %) were females, and the median follow-up time was 69 months. Baseline SLD presence was defined ultrasonographically and was detected in 25 (23.1 %) patients. There were no associations of SLD with any of the clinical and laboratory patient characterictics. Also, baseline ultrasonographic presence of SLD did not have an impact on future thrombotic, bleeding and disease transformation risk, nor patient survival. None of the patients experienced signs of liver failure during the follow-up. In conclusion, the presence of SLD in ET and PV patients does not seem to have major clinical implications. Therefore, patients may be advised about the generally harmless nature of SLD when occurring in the MPN context.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleHeliyon
Numberingvol. 10, no. 12, e32827
p-ISSN2405-8440
DOIhttps://doi.org/10.1016/j.heliyon.2024.e32827
URN:NBNurn:nbn:hr:184:314923
Publication2024-06-11
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S2405844024088583
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-11-11 13:12:40